Posts By: Alnylam Pharmaceuticals

January 3, 2019 John Maraganore Talks RNAi on Chemical & Engineering News Podcast John Maraganore talks with Chemical & Engineering News' Lisa Jarvis and Ryan Cross on this episode of C&EN's Stereo Chemistry podcast. Read More ›
March 29, 2019 Team Alnylam Hits the Court to Support Massachusetts Special Olympics Alnylam joined more than a dozen biotech companies in the annual Bioball Basketball Tournament to support the Massachusetts Special Olympics. Read More ›
May 1, 2019 The Skinner Family - Living with Primary Hyperoxaluria Type 1 Three of the four Skinner children have been diagnosed with primary hyperoxaluria type 1 (PH1). Learn more about their story in this video. Read More ›
August 3, 2018 Barry Greene Named to PharmaVoice 100 "For Being an RNAi Champion" Alnylam President Barry Greene has been named to the PharmaVoice 100 for 2018.  Barry was selected "for being an RNAi champion." Read More ›
May 12, 2019 Ania (UK) - Living with Acute Intermittent Porphyria (AIP) Ania from the UK is living with acute intermittent porphyria (AIP), a type of acute hepatic porphyria (AHP). In this video, she shares her story and thoughts... Read More ›
July 1, 2017 One Family, Three Generations, One Disease - Living with hATTR Amyloidosis Test Read More ›
November 8, 2018 Celebrating Alnylam's 1000th Employee! We were founded 16 years ago on the belief that we could translate the Nobel Prize-winning discovery of RNA interference (#RNAi) into an entirely new class... Read More ›
December 11, 2018 John Maraganore Named to Bloomberg 50 List for 2018 Alnylam CEO John Maraganore has been named to the Bloomberg 50 list for 2018. Read More ›
May 9, 2018 First Rounders: John Maraganore Our CEO John Maraganore, Ph.D. recently chatted with the Nature Biotechnology Podcast about his path into science, through research and ultimately into biotech. Read More ›
August 11, 2018 New Kind of Drug, Silencing Genes, Gets FDA Approval [Wall Street Journal] The following article appeared in The Wall Street Journal on August 10, 2018... "New Kind of Drug, Silencing Genes, Gets FDA Approval"... Read More ›

Get In Touch

Have any questions or comments about the content you see on this page?

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site